ERYTECH Reports Third Quarter 2017 Financial Results and Provides Business Update Post author:admERY Post published:November 6, 2017 Post category:Newsroom ERYTECH today provided a business update and reported its financial results for the quarter ended September 30, 2017. You Might Also Like ERYTECH Reports Top-line Results of Phase 2b Study of Eryaspase for the Treatment of AML December 8, 2017 ERYTECH makes its 2016 Reference Document available April 3, 2017 ERYTECH to report positive initial results on the use of GRASPA® in ALL patients allergic to E. Coli and Erwinia derived asparaginases at ASH November 7, 2014
ERYTECH Reports Top-line Results of Phase 2b Study of Eryaspase for the Treatment of AML December 8, 2017
ERYTECH to report positive initial results on the use of GRASPA® in ALL patients allergic to E. Coli and Erwinia derived asparaginases at ASH November 7, 2014
